Radioligand therapy (RLT) development relies heavily on preclinical data to guide clinical translation, yet important gaps remain between standard rodent models and human biology. As RLT programs advance, developers are increasingly exploring alternative models, including large animals, to better understand biodistribution, dosimetry, safety and target engagement in a more clinically relevant context.
This webinar explores the role of large animal studies within the broader RLT development pathway, from early in vitro and rodent work through to first-in-human considerations. Attendees will gain practical insight into when and why large animal models may be appropriate, how to address translational gaps and how to design studies that generate more predictive data for regulatory and clinical decision-making.
Large animal studies can help strengthen dosimetry projections, safety assessment and translational confidence when conventional models do not fully reflect human biology. The session will also address practical considerations such as cost, ethics and study design trade-offs, giving attendees a clearer framework for selecting the right model at the right stage.
Register for this webinar to learn how radioligand therapy programs can use large animal studies to improve clinical translation and first-in-human planning.
Speaker
Sven Macholl, PhD, Study Director, Perceptive Discovery
Sven Macholl is a Study Director at Perceptive Discovery, where he leads complex preclinical imaging programs and oversees strategic partnerships across the US and Canada. With nearly two decades of experience spanning academia, GE Healthcare and contract research, he brings deep expertise in multimodal imaging, radioligand therapy and radiation dosimetry. Sven has managed approximately 80 studies for more than 25 clients, supporting a wide range of therapeutic modalities and advanced imaging approaches in oncology and beyond. He holds a PhD in NMR crystallography and has a strong background in MRI, PET/SPECT imaging and translational research.
Message PresenterWho Should Attend?
This webinar is ideal for:
- Translational Scientists working in radiopharmaceutical and oncology drug development
- Preclinical Researchers designing RLT efficacy, biodistribution and dosimetry studies
- Radiochemistry and Radiopharmaceutical development teams
- Clinical and Translational Leaders planning IND-enabling strategies
- Biotech and pharma professionals advancing radioligand therapy or theranostic programs
- R&D leaders seeking to improve clinical predictability and reduce translational risk
What You Will Learn
Attendees will gain insights into:
- The role of in vitro, rodent and large animal studies across the RLT development pathway
- Key limitations of rodent models and how these impact clinical translation
- When to consider large animal models in RLT programs
- How species differences in target expression, metabolism and biodistribution affect study outcomes
- Approaches to improve dosimetry predictions and safety assessment for first-in-human studies
- Strategies to generate data that meet both scientific and regulatory expectations
- Practical considerations, including cost, ethics and study design trade-offs
Xtalks Partner
Perceptive Discovery
Perceptive Discovery bridges the gap between preclinical insights and early clinical success, providing the expertise and high-quality data needed to advance innovation with confidence. With deep expertise in advanced imaging, radiochemistry, and translational science, we specialize in supporting drug development programs across CNS, oncology, and radioligand therapy. Our integrated approach combines rigorous scientific analysis, state-of-the-art imaging platforms, and multidisciplinary expertise to deliver data that drives smarter decisions, reduces risk, and accelerates timelines from preclinical to first-in-human studies.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account